Arch Therapeutics : Initial statement of beneficial ownership of securities
August 11, 2021 at 05:21 pm EDT
Share
FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden hours per response...
0.5
(Print or Type Responses)
1. Name and Address of Reporting Person *
Yrigoyen Dan
2. Date of Event Requiring Statement (Month/Day/Year)
07/12/2021
3. Issuer Name and Ticker or Trading Symbol
Arch Therapeutics, Inc. [ARTH]
(Last)
(First)
(Middle)
C/O ARCH THERAPEUTICS, INC., 235 WALNUT STREET, SUITE 6
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director
_____ 10% Owner
__X__ Officer (give title below)
_____ Other (specify below)
Vice President, Sales
5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)
FRAMINGHAM, MA 01702
6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
2. Date Exercisable and Expiration Date
(Month/Day/Year)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security
5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable
Expiration Date
Title
Amount or Number of Shares
Reporting Owners
Reporting Owner Name / Address
Relationships
Director
10% Owner
Officer
Other
Yrigoyen Dan
C/O ARCH THERAPEUTICS, INC.
235 WALNUT STREET, SUITE 6
FRAMINGHAM, MA 01702
Vice President, Sales
Signatures
/s/ Dan Yrigoyen
08/11/2021
**Signature of Reporting Person
Date
Explanation of Responses:
No securities are beneficially owned
*
If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**
Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
Attachments
Original document
Permalink
Disclaimer
Arch Therapeutics Inc. published this content on 11 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 August 2021 21:19:09 UTC.
Arch Therapeutics, Inc. is a biotechnology company developing and marketing products based on its AC5 self-assembling technology platform. These products can be advances in the field of stasis and barrier applications. The Companyâs flagship products and product candidates are derived from its AC5 self-assembling peptide (SAP) technology platform and referred to as AC5 or the AC5 Devices. These include AC5 Advanced Wound System and AC5 Topical Hemostat, which are intended for skin applications, such as management of complicated chronic wounds and acute surgical wounds. Other products are in development for use in minimally invasive or open surgical procedures and include AC5-GTM for gastrointestinal endoscopic procedures and AC5-V and AC5 Surgical Hemostat for hemostasis inside the body. It is developing BioSurgery products for internal use, including for hemostasis and sealant applications, and gastrointestinal endoscopic surgical procedures.